From soundwaves to
state-of-the-art drug delivery
Nebu~Flow’s unique, patented aerosol formation technology uses acoustic waves to aerosolise a far greater range of drug formulations, including biologics, peptides and RNA therapeutics, making them suitable for inhalation via a nebuliser. The result is a precise, cost-effective and convenient platform for drug delivery – bringing nebulisation up to date for the needs of today and the drugs of tomorrow.
Powering tomorrow’s inhaled therapies
Fast, effective and with fewer side effects: respiratory drug delivery has many benefits. Our lungs have a huge surface area and an extremely thin air-blood barrier, meaning that drugs can enter the bloodstream as quickly as they would via intravenous injection. Bypassing the liver can make lower doses effective, with fewer systemic side effects. And unlike injections, inhalation is pain-free.
Currently, only a limited number of drug formulations are suitable for nebulisation, because existing nebulisers damage fragile molecules. Nebu~Flow’s proprietary technology enables respiratory delivery of hard-to-nebulise biologic drugs, paving the way for new treatments with a far better patient experience.

About Nebu~Flow
Led by a respected, experienced team, Nebu~Flow has built momentum with high-value pharma collaborations and £11.2m of funding to date. With five patent families secured, prototype devices and active engagement with patients, carers and healthcare providers, Nebu~Flow is on course to deliver a more effective, efficient and sustainable platform for tomorrow’s life-changing therapies.








